Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGRX | Common Stock | Purchase | $4.87M | +5.73M | +36.02% | $0.85 | 21.7M | Oct 13, 2021 | See footnote | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGRX | Warrants (right to buy) | Purchase | +2.69M | 2.69M | Oct 13, 2021 | Common Stock | 2.69M | $0.85 | See footnote | F1, F2 |
Id | Content |
---|---|
F1 | The securities reported on this Form 4 were acquired as a unit, with each unit consisting of one share of common stock and one-half of a warrant to purchase one share of common stock, with a combined price of $0.85 per unit. The warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer???s outstanding shares of common stock following the exercise. |
F2 | The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |